Literature DB >> 17390394

Non-myeloablative mixed chimerism approaches and tolerance, a split decision.

Bin Luo1, William F N Chan, A M James Shapiro, Colin C Anderson.   

Abstract

Stable mixed chimerism has been considered the most robust tolerance strategy. However, rejection of solid donor tissues by chimeras has been observed, a state termed split tolerance. Since new non-myeloablative mixed chimerism approaches are being actively pursued, we sought to determine whether they lead to full tolerance or split tolerance and to define the mechanisms involved. Fully mismatched mixed chimeras generated by induction with various lymphocyte-depleting antibodies along with either low-dose irradiation or busulfan and temporary sirolimus, maintained stable mixed chimerism but nevertheless rejected donor skin grafts. Generation of stable mixed chimerism using antibody targeting CD40L, but not depleting antibodies to CD4 and CD8, could prevent split tolerance when skin grafts were given together with donor bone marrow. Minor antigen matching abrogated the ability of effector T cells to reject donor skin grafts. A CFSE killing assay indicated that chimeras were both directly and indirectly tolerant of donor hematopoietic cell antigens, suggesting that minor mismatches triggered a tissue-specific response. Thus, split tolerance due to tissue-restricted polymorphic antigens prevents full tolerance in a number of non-myeloablative mixed chimerism protocols and a 'tolerizing' agent is required to overcome split tolerance. A model of the requirements for split tolerance is presented.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17390394     DOI: 10.1002/eji.200636938

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  Mixed chimerism and split tolerance: mechanisms and clinical correlations.

Authors:  David P Al-Adra; Colin C Anderson
Journal:  Chimerism       Date:  2011 Oct-Dec

2.  Split immunological tolerance to trophoblast.

Authors:  Amanda de Mestre; Leela Noronha; Bettina Wagner; Douglas F Antczak
Journal:  Int J Dev Biol       Date:  2010       Impact factor: 2.203

3.  Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes.

Authors:  Olivier Joffre; Thibault Santolaria; Denis Calise; Talal Al Saati; Denis Hudrisier; Paola Romagnoli; Joost P M van Meerwijk
Journal:  Nat Med       Date:  2007-12-09       Impact factor: 53.440

Review 4.  Mechanisms of Tolerance Induction by Hematopoietic Chimerism: The Immune Perspective.

Authors:  Esma S Yolcu; Haval Shirwan; Nadir Askenasy
Journal:  Stem Cells Transl Med       Date:  2017-01-03       Impact factor: 6.940

5.  Hematopoietic chimerism and transplantation tolerance: a role for regulatory T cells.

Authors:  Lise Pasquet; Olivier Joffre; Thibault Santolaria; Joost P M van Meerwijk
Journal:  Front Immunol       Date:  2011-12-28       Impact factor: 7.561

Review 6.  Transplantation tolerance: lessons from experimental rodent models.

Authors:  Cherry I Kingsley; Satish N Nadig; Kathryn J Wood
Journal:  Transpl Int       Date:  2007-08-17       Impact factor: 3.782

7.  Signal one and two blockade are both critical for non-myeloablative murine HSCT across a major histocompatibility complex barrier.

Authors:  Kia J Langford-Smith; Zara Sandiford; Alex Langford-Smith; Fiona L Wilkinson; Simon A Jones; J Ed Wraith; Robert F Wynn; Brian W Bigger
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

8.  Donor-Specific Regulatory T Cell-Mediated Immune Tolerance in an Intrahepatic Murine Allogeneic Islet Transplantation Model with Short-Term Anti-CD154 mAb Single Treatment.

Authors:  Seok-Joo Lee; Hyun-Je Kim; Na-Ri Byun; Chung-Gyu Park
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.